Business Description
Cryosite Ltd
ISIN : AU000000CTE1
Description
Cryosite Ltd is engaged in the provision of supply chain logistics, management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.35 | |||||
Equity-to-Asset | 0.13 | |||||
Debt-to-Equity | 0.87 | |||||
Debt-to-EBITDA | 0.98 | |||||
Interest Coverage | 442.25 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.68 | |||||
Beneish M-Score | -2.29 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.2 | |||||
3-Year EBITDA Growth Rate | 3 | |||||
3-Year EPS without NRI Growth Rate | -1.1 | |||||
3-Year FCF Growth Rate | 42.2 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 78.04 | |||||
9-Day RSI | 75.97 | |||||
14-Day RSI | 75.19 | |||||
6-1 Month Momentum % | 76.86 | |||||
12-1 Month Momentum % | 71.2 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.31 | |||||
Quick Ratio | 2.29 | |||||
Cash Ratio | 1.46 | |||||
Days Inventory | 4.73 | |||||
Days Sales Outstanding | 52.75 | |||||
Days Payable | 67.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 5.2 | |||||
Dividend Payout Ratio | 0.47 | |||||
Forward Dividend Yield % | 5.2 | |||||
5-Year Yield-on-Cost % | 5.2 | |||||
3-Year Average Share Buyback Ratio | -1.4 | |||||
Shareholder Yield % | 2.31 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 60.86 | |||||
Operating Margin % | 14.02 | |||||
Net Margin % | 12.49 | |||||
FCF Margin % | 14.87 | |||||
ROE % | 61.16 | |||||
ROA % | 7.24 | |||||
ROIC % | 9.81 | |||||
ROC (Joel Greenblatt) % | 55.05 | |||||
ROCE % | 10.22 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 39.06 | |||||
PE Ratio without NRI | 39.06 | |||||
Shiller PE Ratio | 121.32 | |||||
Price-to-Owner-Earnings | 33.51 | |||||
PEG Ratio | 0.63 | |||||
PS Ratio | 4.85 | |||||
PB Ratio | 21.19 | |||||
Price-to-Tangible-Book | 20.83 | |||||
Price-to-Free-Cash-Flow | 32.89 | |||||
Price-to-Operating-Cash-Flow | 26.59 | |||||
EV-to-EBIT | 31.37 | |||||
EV-to-EBITDA | 22.34 | |||||
EV-to-Revenue | 4.57 | |||||
EV-to-FCF | 30.45 | |||||
Price-to-Projected-FCF | 8.33 | |||||
Price-to-Median-PS-Value | 3.91 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.71 | |||||
Price-to-Graham-Number | 5.95 | |||||
Earnings Yield (Greenblatt) % | 3.19 | |||||
FCF Yield % | 3.08 | |||||
Forward Rate of Return (Yacktman) % | 20.59 |